Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets

  • Sanofi SA (NASDAQ:SNY) and Seagen Inc (NASDAQ:SGEN) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. 
  • The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. 
  • ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein, and Sanofi currently has one ADC in development.
  • Under the terms of the collaboration, Seagen and Sanofi will co-fund global development activities and share equally in any future profits. 
  • In addition, Sanofi will make an undisclosed payment to Seagen for each of the three targets as they are selected. 
  • The first target under the collaboration has already been designated.
  • Price Action: SGEN stock closed 0.54% higher at $137.60 on Tuesday. SNY shares are up 0.14% at $51.90 during the premarket session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.